Farther Finance Advisors LLC Has $47,000 Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Farther Finance Advisors LLC increased its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 123.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 3,575 shares of the company’s stock after purchasing an additional 1,976 shares during the quarter. Farther Finance Advisors LLC’s holdings in Takeda Pharmaceutical were worth $47,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in shares of Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after buying an additional 286,052 shares during the last quarter. Van ECK Associates Corp lifted its holdings in shares of Takeda Pharmaceutical by 1.6% during the fourth quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock worth $29,266,000 after buying an additional 35,192 shares during the last quarter. Managed Asset Portfolios LLC lifted its holdings in shares of Takeda Pharmaceutical by 0.3% during the third quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company’s stock worth $23,001,000 after buying an additional 4,069 shares during the last quarter. Stifel Financial Corp lifted its holdings in shares of Takeda Pharmaceutical by 103.9% during the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after buying an additional 224,594 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in shares of Takeda Pharmaceutical by 2.9% during the third quarter. Quantinno Capital Management LP now owns 361,713 shares of the company’s stock worth $5,144,000 after buying an additional 10,258 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 0.2 %

Shares of TAK stock opened at $15.20 on Monday. The stock has a market cap of $48.35 billion, a P/E ratio of 37.99, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.31. The stock has a fifty day moving average price of $13.96 and a 200 day moving average price of $13.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.